SARS-CoV-2 rORF3, a novel microprotein, impairs interferon-β production by targeting RanBP2 to inhibit p65 nuclear import
Yucong Huang, Jing Jiang, Qingting Xiao, Yajie Wang, Gulinaziya Abulaike, Ayinuer Maimaiti, Pan Gong, Xiaohuang Lin, Fangfang Li, Xueping Zhou, Alexander F. Palazzo, Qingtang Shen
Journal:INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
IF:8.5
DOI:10.1016/j.ijbiomac.2026.150557
PMID:
Published:2026-01-27
research field:生物材料传染病免疫学微生物学材料科学
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the coronavirus disease 2019 (COVID-19). SARS-CoV-2 encodes various proteins to evade host innate immunity. rORF3 is a novel microprotein encoded by the negative-strand RNA (-RNA) of SARS-CoV-2 that antagonizes type I interferon (IFN-I) production. However, the molecular mechanism by which SARS-CoV-2 rORF3 suppresses IFN-I production remains elusive. Here we report rORF3 interacts with a nucleoporin Ran-Binding Protein 2 (RanBP2), and suppresses IFN-β production and promotes viral infection in a RanBP2-dependent manner. Specifically, we found RanBP2 inhibits the RIG-I-like receptor (RLR)-mediated signaling by targeting p65 and suppressing the nuclear translocation of p65. rORF3 targets RanBP2 and impedes the nuclear translocation of p65 upon tumor necrosis factor-alpha (TNF-α) stimulation, thereby antagonizing IFN-β production. Our findings not only reveal a novel function of RanBP2 in regulating RLR signaling but also provide insights into a new mechanism of the innate immune evasion by SARS-CoV-2.
本文使用的Yeasen产品


